Nanobac Pharmaceuticals Company Description
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs).
It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs.
The company’s diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases.
Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002.
The company was founded in 1994 and is based in Tampa, Florida.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | John Stanton |
Contact Details
Address: 3000 Bayport Drive Tampa, Florida 33607 United States | |
| Phone | 813-865-1125 |
Stock Details
| Ticker Symbol | NNBP |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US63007M1027 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John M. Stanton | Chairman, Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer |
| Benedict Salvadore Maniscalco M.D. | Director of Clinical Research, Medical Director and Director |
| Dr. Neva Ciftcioglu | Co-Founder, Director of Science and Scientific Advisor |
| Dr. E. Olavi Kajander | Chief Science and Research Officer and MD of Nanobac OY |